We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$177M
AUM Growth
-$67.5M
Cap. Flow
-$24.6M
Cap. Flow %
-13.91%
Top 10 Hldgs %
45.17%
Holding
74
New
27
Increased
–
Reduced
22
Closed
22

Top Buys

1
CELG
Celgene Corp
CELG
+$9.29M
2
BSX icon
Boston Scientific
BSX
+$7.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.44M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.11M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.99M

Top Sells

1
AMGN icon
Amgen
AMGN
+$12.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$10.1M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$10.1M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$7.85M
5
BLUE
bluebird bio
BLUE
+$7.71M

Sector Composition

1 Healthcare 61.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCRX
51
DELISTED
Ocera Therapeutics, Inc.
OCRX
$132K 0.07%
45,000
-80,000
-64% -$228K
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-45,000
Closed -$4.24M
AMGN icon
53
Amgen
AMGN
$198B
– –
-75,000
Closed -$12.2M
BIIB icon
54
Biogen
BIIB
$30.4B
– –
-25,000
Closed -$7.66M
BLUE
55
DELISTED
bluebird bio
BLUE
– –
-9,264
Closed -$7.71M
CPRX icon
56
Catalyst Pharmaceutical
CPRX
– –
-376,000
Closed -$921K
DVAX
57
DELISTED
Dynavax Technologies
DVAX
– –
-55,000
Closed -$1.33M
FOLD
58
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-100,000
Closed -$970K
INCY icon
59
Incyte
INCY
$23.4B
– –
-50,000
Closed -$5.42M
LAB icon
60
Standard BioTools
LAB
$350M
– –
-150,000
Closed -$1.62M
PCRX icon
61
Pacira BioSciences
PCRX
$1.01B
– –
-30,000
Closed -$2.3M
PRTA icon
62
Prothena Corp
PRTA
$453M
– –
-90,000
Closed -$6.13M
RGNX icon
63
Regenxbio
RGNX
$511M
– –
-60,000
Closed -$996K
SRPT icon
64
Sarepta Therapeutics
SRPT
$1.82B
– –
-100,000
Closed -$3.86M
TNXP icon
65
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– -$2.69M
TVTX icon
66
Travere Therapeutics
TVTX
$5.27B
– –
-200,000
Closed -$3.86M
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-225,000
Closed -$10.1M
ACOR
68
DELISTED
Acorda Therapeutics
ACOR
– –
-833
Closed -$4.28M
CLVS
69
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-50,000
Closed -$1.75M
FPRX
70
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-100,000
Closed -$4.15M
MNK
71
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-135,000
Closed -$10.1M
SGYP
72
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-600,000
Closed -$3.4M
CORI
73
DELISTED
Corium International, Inc.
CORI
– –
-125,000
Closed -$1.01M
ZLTQ
74
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-275,000
Closed -$7.85M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Ghost Tree Capital held 74 positions worth $177M, down 28% from $244M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ghost Tree Capital withdrew a net $24.6M in Q1 2016, closing 22 positions and reducing 22 holdings. Its most notable exit was Amgen, an estimated $12.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 90% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Celgene Corp worth $9.03M.

  • Ghost Tree Capital's largest Q1 2016 buy was Celgene Corp: 90,202 shares worth $9.03M.
  • Ghost Tree Capital's biggest Q1 2016 reduction was NuVasive, Inc., cutting an estimated $7.26M.
  • Ghost Tree Capital fully exited Amgen in Q1 2016, selling an estimated $12.2M.
  • Ghost Tree Capital's ten largest holdings make up 45% of its $177M portfolio in Q1 2016.
  • Ghost Tree Capital opened 27 new positions and closed 22 in Q1 2016.
  • Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $177M.

Based on Ghost Tree Capital's 13F filing for Q1 2016, filed 13 May 2016.